Dow has contracted Cambrex to make its solubility enhancing polymer HPMCAS, adding manufacturing clout to its bioavailability-focused collaboration with Bend Research.

The deal will see the Cambrex manufacture Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Dow, thereby becoming a third player in a collaboration Dow made last October over the development of spray-drying based solutions with Bend Research
.

No financial information regarding the collaboration with Cambrex was disclosed though the contract manufacturing organization (CMO) has begun work at its facility in Sweden specifically to attain Dow’s target of late 2013 to enter the market with solubility enabling excipient.

HPMCAS

As a compound proven to be effective at maintaining supersaturation and creating homogenous bioavailability formulations, Dow has taken HPMCAS and will - according to Knabe - offer unique tailoring with each Active Pharmaceutical Ingredient (API) in order to address the bioavailability issue.

Bioavailability is a continuing issue for pharma companies as they look for ways of improving API efficacy as trends in drugs move towards more complex and less soluble molecules.

Knabe described the challenge: “It is estimated that more than 40% and perhaps as much as 80% of new molecular entities now suffer from poor aqueous solubility and therefore are susceptible to poor oral absorption.”

On the 20th March the Bioavailability Challenge will be addressed in a special online event, organized by in-Pharmatechnologist.com. For more information on speakers and how to gain access to the event, please click here
.

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below: